International audienceRisk factors for long-term non-motor symptoms and quality of life following subthalamic nucleus deep brain stimulation (STN DBS) have not yet been fully identified. In the present study, we investigated the impact of motor symptom asymmetry in Parkinson’s disease. Data were extracted for 52 patients with Parkinson’s disease (half with predominantly left-sided motor symptoms and half with predominantly right-sided ones) who underwent bilateral STN and a matched healthy control group. Performances for cognitive tests, apathy and depression symptoms, as well as quality-of-life questionnaires at 12 months post-DBS were compared with a pre-DBS baseline. Results indicated a deterioration in cognitive performance post-DBS in ...
The physical benefits of subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson’s disease...
The effects of subthalamic nucleus (STN) stimulation on cognition and mood have not been well establ...
Nonmotor symptoms are an integral part of Parkinson’s disease and cause significant morbidity. Pharm...
International audienceRisk factors for long-term non-motor symptoms and quality of life following su...
Subthalamic deep brain stimulation (STN DBS) is an established treatment for the motor symptoms in p...
Subthalamic deep brain stimulation (STN DBS) is an established treatment for the motor symptoms in p...
Objective To examine 36-month effects of bilateral subthalamic nucleus deep brain stimulation (STN-D...
To evaluate how bilateral subthalamic nucleus deep brain stimulation (STN-DBS) affects visuo-motor c...
Objective To find predictors of cognitive decline and quality of life 1 year after bilateral subthal...
Background: The objective of this study was to investigate 24-month of effects of bilateral subthala...
Non-motor symptoms (NMS), such as neuropsychiatric, neuropsychological, autonomic, sensory, and slee...
Abstract To identify predictors of 36-month follow-up quality of life (QoL) outcome after bilateral ...
Objective To find predictors of cognitive decline and quality of life 1 year after bilateral subthal...
Objective To examine 36-month effects of bilateral subthalamic nucleus deep brain stimulation (STN-D...
To identify predictors of 36-month follow-up quality of life (QoL) outcome after bilateral subthalam...
The physical benefits of subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson’s disease...
The effects of subthalamic nucleus (STN) stimulation on cognition and mood have not been well establ...
Nonmotor symptoms are an integral part of Parkinson’s disease and cause significant morbidity. Pharm...
International audienceRisk factors for long-term non-motor symptoms and quality of life following su...
Subthalamic deep brain stimulation (STN DBS) is an established treatment for the motor symptoms in p...
Subthalamic deep brain stimulation (STN DBS) is an established treatment for the motor symptoms in p...
Objective To examine 36-month effects of bilateral subthalamic nucleus deep brain stimulation (STN-D...
To evaluate how bilateral subthalamic nucleus deep brain stimulation (STN-DBS) affects visuo-motor c...
Objective To find predictors of cognitive decline and quality of life 1 year after bilateral subthal...
Background: The objective of this study was to investigate 24-month of effects of bilateral subthala...
Non-motor symptoms (NMS), such as neuropsychiatric, neuropsychological, autonomic, sensory, and slee...
Abstract To identify predictors of 36-month follow-up quality of life (QoL) outcome after bilateral ...
Objective To find predictors of cognitive decline and quality of life 1 year after bilateral subthal...
Objective To examine 36-month effects of bilateral subthalamic nucleus deep brain stimulation (STN-D...
To identify predictors of 36-month follow-up quality of life (QoL) outcome after bilateral subthalam...
The physical benefits of subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson’s disease...
The effects of subthalamic nucleus (STN) stimulation on cognition and mood have not been well establ...
Nonmotor symptoms are an integral part of Parkinson’s disease and cause significant morbidity. Pharm...